Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T22:43:52.670Z.
Calculation as of: 2026-10-06T22:43:52.670Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 48a9c173a70739b1093346a936f860d9c8f80d7eeb2565194c7199b3c596865c
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Market Cap
$376.01M
EV/Sales Ratio
1.45x
TTM Avg
1.43x
3Y Avg
2.68x
5Y Avg
18.63x
Market Cap
$374.50M
EV/Sales Ratio
N/A
TTM Avg
4250.23x
3Y Avg
4250.23x
5Y Avg
4250.23x
Market Cap
$380.37M
EV/Sales Ratio
0.61x
TTM Avg
0.77x
3Y Avg
0.83x
5Y Avg
0.91x
Market Cap
$369.50M
EV/Sales Ratio
8.44x
TTM Avg
2.21x
3Y Avg
2.18x
5Y Avg
9.49x
Market Cap
$361.64M
EV/Sales Ratio
31.23x
TTM Avg
114.38x
3Y Avg
98.11x
5Y Avg
98.11x
Market Cap
$359.53M
EV/Sales Ratio
5.37x
TTM Avg
5.77x
3Y Avg
8.21x
5Y Avg
104.30x
Market Cap
$396.93M
EV/Sales Ratio
6.45x
TTM Avg
6.44x
3Y Avg
6.66x
5Y Avg
6.66x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Zura Bio Limited (ZURA) | $376.19M | N/A | N/A | N/A | N/A |
| Canopy Growth Corporation (CGC)vs › | $376.01M | 1.45x | 1.43x | 2.68x | 18.63x |
| Kyverna Therapeutics, Inc. (KYTX)vs › | $374.50M | N/A | 4250.23x | 4250.23x | 4250.23x |
| Orthofix Medical Inc. (OFIX)vs › | $380.37M | 0.61x | 0.77x | 0.83x | 0.91x |
| Arcturus Therapeutics Holdings Inc. (ARCT)vs › | $369.50M | 8.44x | 2.21x | 2.18x | 9.49x |
| REGENXBIO Inc. (RGNX)vs › | $385.15M | 2.39x | 4.70x | 5.76x | 5.75x |
| Opus Genetics, Inc. (IRD)vs › | $361.64M | 31.23x | 114.38x | 98.11x | 98.11x |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $359.53M | 5.37x | 5.77x | 8.21x | 104.30x |
| Shoulder Innovations, Inc. (SI)vs › | $396.93M | 6.45x | 6.44x | 6.66x | 6.66x |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $355.43M | N/A | 50.09x | 50.09x | 50.09x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
